These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy. Zhang X; Wang L; Liu M; Li D Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255 [TBL] [Abstract][Full Text] [Related]
25. Non-viral delivery of genome-editing nucleases for gene therapy. Wang M; Glass ZA; Xu Q Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355 [TBL] [Abstract][Full Text] [Related]
26. CRISPR: From Prokaryotic Immune Systems to Plant Genome Editing Tools. Bandyopadhyay A; Mazumdar S; Yin X; Quick WP Adv Exp Med Biol; 2017; 1016():101-120. PubMed ID: 29130156 [TBL] [Abstract][Full Text] [Related]
28. Therapy Development by Genome Editing of Hematopoietic Stem Cells. Koniali L; Lederer CW; Kleanthous M Cells; 2021 Jun; 10(6):. PubMed ID: 34198536 [TBL] [Abstract][Full Text] [Related]
29. Unraveling the potential of CRISPR-Cas9 for gene therapy. Barrangou R; May AP Expert Opin Biol Ther; 2015 Mar; 15(3):311-4. PubMed ID: 25535790 [TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Sharma G; Sharma AR; Bhattacharya M; Lee SS; Chakraborty C Mol Ther; 2021 Feb; 29(2):571-586. PubMed ID: 33238136 [TBL] [Abstract][Full Text] [Related]
31. A beginner's guide to gene editing. Harrison PT; Hart S Exp Physiol; 2018 Apr; 103(4):439-448. PubMed ID: 29282799 [TBL] [Abstract][Full Text] [Related]
32. Recent advances in CRISPR technologies for genome editing. Song M; Koo T Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771 [TBL] [Abstract][Full Text] [Related]
33. Expanding the Toolbox and Targets for Gene Editing. Dan J; Memczak S; Izpisua Belmonte JC Trends Mol Med; 2021 Mar; 27(3):203-206. PubMed ID: 33487569 [TBL] [Abstract][Full Text] [Related]
34. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential. Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021 [TBL] [Abstract][Full Text] [Related]
35. Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy. de Morais CCPL; Correia EM; Bonamino MH; Vasconcelos ZFM Hum Gene Ther; 2024 Oct; 35(19-20):781-797. PubMed ID: 39276086 [TBL] [Abstract][Full Text] [Related]
36. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research. Li ZH; Wang J; Xu JP; Wang J; Yang X Mil Med Res; 2023 Mar; 10(1):12. PubMed ID: 36895064 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic gene editing in haematological disorders with CRISPR/Cas9. Jensen TI; Axelgaard E; Bak RO Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164 [TBL] [Abstract][Full Text] [Related]
38. The Future of CRISPR Applications in the Lab, the Clinic and Society. Hough SH; Ajetunmobi A Adv Exp Med Biol; 2017; 1016():157-178. PubMed ID: 29130159 [TBL] [Abstract][Full Text] [Related]
39. CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases. Khan FA; Pandupuspitasari NS; Chun-Jie H; Ao Z; Jamal M; Zohaib A; Khan FA; Hakim MR; ShuJun Z Oncotarget; 2016 Aug; 7(32):52541-52552. PubMed ID: 27250031 [TBL] [Abstract][Full Text] [Related]